X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
    Tomsk Cancer Research Institute ; 2018
    In:  Siberian journal of oncology Vol. 17, No. 3 ( 2018-07-04), p. 11-19
    Details
    In: Siberian journal of oncology, Tomsk Cancer Research Institute, Vol. 17, No. 3 ( 2018-07-04), p. 11-19
    Abstract: More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable  tumors receive adjuvant endocrine therapy. Patients with metastatic  ER+ breast cancer also receive hormone therapy as first-line  treatment. Patients with ER+/PR+ locally advanced breast cancer  including potentially operable cases (cT2N1, cT3N0M0) are still a  subject to neoadjuvant chemotherapy in most of the oncology  centers in Russia and worldwide. More than 10 years ago, several  trials evaluating the efficacy of neoadjuvant endocrine therapy were  conducted in the Petrov Research Institute of Oncology (aromatase  inhibitors vs tamoxifen, neoadjuvant endocrine therapy vs  neoadjuvant chemotherapy, etc.) The primary endpoint was the  evaluation of pathologic complete/partial response to therapy and  the frequency of breast-conserving surgeries following neoadjuvant  treatment. We now represent 10-year long-term follow-up data on  comparison of neoadjuvant chemotherapy with neoadjuvant  endocrine therapy after retrospective determination of IHC- phenotypes of 239 patients with ER+ breast cancer. The study  results show tendency to better 10-year disease-free survival in  patients with luminal-A breast cancer who received endocrine  therapy compared to neoadjuvant chemotherapy (72.8 % vs 53.9  %, respectively, p=0.062) There were no statistically significant  differences in DFS rates among patients with the luminal B breast  cancer subtype (41 % vs 40 %) The discovery of biomarkers of  potential resistance to endocrine therapy (cycline-dependant kinase  activity [cdk 4/6] , estrogenreceptor mutation [ESR1], mTOR  signaling pathway activity, co-expression of the ER and HER2neu  [ER+/ HER2neu3+] ) and ways to inhibit the activity of the resistance pathways (palbocyclib, everolimus, etc.) have expanded the  armamentarium of endocrine-therapy for not only metastatic and  locally-advanced but also operable cases of ER+ breast cancer.
    Type of Medium: Online Resource
    ISSN: 2312-3168 , 1814-4861
    URL: Issue
    URL: Article
    DOI: 10.21294/1814-4861-2018-17-3
    DOI: 10.21294/1814-4861-2018-17-3-11-19
    Language: Unknown
    Publisher: Tomsk Cancer Research Institute
    Publication Date: 2018
    detail.hit.zdb_id: 2693095-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 2
    Online Resource
    Online Resource
    Comparative analysis of tumor control gene and microRNA expression profiles in tumor and adjacent tissues in patients with colorectal cancer
    Tomsk Cancer Research Institute ; 2022
    In:  Siberian journal of oncology Vol. 21, No. 2 ( 2022-05-05), p. 55-64
    Details
    In: Siberian journal of oncology, Tomsk Cancer Research Institute, Vol. 21, No. 2 ( 2022-05-05), p. 55-64
    Abstract: Background. Various tumor control genes and microRNAs (miRNa) play an important role in the development and progression of colorectal cancer (CRC). the expression of these genes can differ significantly in tumor and adjacent healthy tissues. there is no exact data at what distance from the tumor the adjacent healthy tissue is located in terms of gene expression. The aim of the investigation was to study the tumor control genes ( E2F3, TGFB, NFKB, KLF-12, EGFR and MMP9 ), as well as the microRNA genes ( microRNA-15, -16, -21 and -210 ) expression profiles in tumor and adjacent healthy tissues. Material and methods. the study included 19 patients diagnosed with colorectal cancer. the tumor control genes ( E2F3, TGFB, NFKB, KLF-12, EGFR and MMP9 ), as well as the miRNA genes ( miRNA-15, -16, -21 and -210 ) expression levels were investigated in tumor and adjacent normal tissue samples taken during colonoscopy. Results. a decrease in the level of expression of E2F3 (median 3,73, Q1-Q3 2,64 Reu vs. median 6.5, Q1-Q3 6,39 REU, p=0,01) and miRNA-16 (median 2,83, Q1-Q3 4,74 REU vs. median 4,29, Q1-Q3 3,73 REU, p=0,027) and an increase in the expression level of miRNA-21 (median 2,64, Q1-Q3 1,38 REU vs. median 1,41, Q1-Q3 1,21 REU, p 〈 0,001) were found in tumor tissue compared to normal tissue of patients with CRC. Conclusion. significant differences in the E2F3, miRNA-16 and miRNA-21 gene expressions were revealed. an increased level of E2F3 and miRNA-16 expressions at a distance of 1–2 cm from the tumor may be a predictor of tumor recurrence and progression, and an increased miRNA-21 expression in tumor tissue as compared to adjacent tissue may be a negative prognostic factor. this information can be used in further clinical research.
    Type of Medium: Online Resource
    ISSN: 2312-3168 , 1814-4861
    URL: Issue
    URL: Article
    DOI: 10.21294/1814-4861-2022-21-2
    DOI: 10.21294/1814-4861-2022-21-2-55-64
    Language: Unknown
    Publisher: Tomsk Cancer Research Institute
    Publication Date: 2022
    detail.hit.zdb_id: 2693095-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 3
    Online Resource
    Online Resource
    THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE
    Tomsk Cancer Research Institute ; 2021
    In:  Siberian journal of oncology Vol. 20, No. 5 ( 2021-10-31), p. 149-161
    Details
    In: Siberian journal of oncology, Tomsk Cancer Research Institute, Vol. 20, No. 5 ( 2021-10-31), p. 149-161
    Abstract: Challenges in cancer detection, prognosis and management are currently being solved by determining circulating tumor DNA (ctDNA). The assessment of this marker has acquired particular importance in metastatic colorectal cancer (mCRC), the systemic treatment of which depends on the RAS gene status, which has prognostic and predictive value. However, the possibilities of taking samples from the primary or metastatic lesion for pathomorphological and molecular analysis in CRC are often limited. The determination of ctDNA using liquid biopsy has an advantage over standard biopsy due to its low invasiveness and high availability of the method. Analysis of mutations using ctDNA as well as changes in the level of this marker is a criterion for the effectiveness of systemic treatment, as well as a factor that determines the risk of disease progression. Currently, the potential of using ctDNA to monitor effectiveness of first-and second-line chemotherapy, as well as to predict the development of secondary resistance to EGFR inhibitors (cetuximab and panitumumab) in the first-line treatment and assessment of RAS status for returning to therapy with EGFR inhibitors in the third-line treatment of mCRC is being studied. Several pilot studies have provided evidence of the efficacy of EGFR re-treatment. The modern literature data published in leading peer-reviewed journals in Russian and international scientific citation databases, such as Medline, Elibrary, and PubMed were analyzed. Of the 138 analyzed publications, 56 were used to write this review. 
    Type of Medium: Online Resource
    ISSN: 2312-3168 , 1814-4861
    URL: Issue
    URL: Article
    DOI: 10.21294/1814-4861-2021-20-5
    DOI: 10.21294/1814-4861-2021-20-5-149-161
    Language: Unknown
    Publisher: Tomsk Cancer Research Institute
    Publication Date: 2021
    detail.hit.zdb_id: 2693095-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 4
    Online Resource
    Online Resource
    MICRORNA IN MONITORING OF THE EVOLUTION OF GLIAL CEREBRAL TUMORS
    Tomsk Cancer Research Institute ; 2020
    In:  Siberian journal of oncology Vol. 19, No. 3 ( 2020-07-06), p. 47-53
    Details
    In: Siberian journal of oncology, Tomsk Cancer Research Institute, Vol. 19, No. 3 ( 2020-07-06), p. 47-53
    Abstract: Glial cerebral tumors (GCT) are primary tumors of the central nervous system that develop from glial tissue. Despite the use of combination treatment, the overall median survival rate in patients with glioblastoma, the most malignant form of HCC, is low. MicroRNA is a large class of endogenous small RNA molecules that inhibit mRNA translation of target genes involved in the evolution of GCT. It was shown that miRNA-21 has antiapoptotic and invasive functions by means of silencing of the PTEN tumor suppressor. MicroRNA-128 can activate a number of genes that are responsible for the mechanisms of suppression of tumor growth. MicroRNA-342, modulating PAK4 gene expression, is involved in the control of tumor cell proliferation, invasion and apoptosis. The aim of the work was to study the feasibility of using the assessment of miRNA-21, -128 and -342 expressions in the blood plasma and saliva of patients to monitor GCT progression or stabilization during combined modality treatment. Material and Methods . The main group consisted of 56 patients with GCTs. (34 men and 22 women), aged 25 to 72 years (average age 48.5 years) GCTs. The control group consisted of 50 people (45 volunteers and 5 neurosurgical patients with extracerebral meningiomas). The study of miRNA-21, -128, and -342 expressions was carried out according to the semiquantitative StemLoopRealTime protocol, using small U6 RNA as a reference gene. Data was processed using the STATISTICA for Windows computer system. Results . In 70 % of patients with disease progression assessed by magnetic resonance imaging, without progression in cerebral and focal neurological signs, the expression level of miRNA21 exceeded the control values both in blood plasma and saliva, and the expression levels of miRNA-128 and -342 were significantly reduced. In patients with GCT stabilization, the expression levels of miRNA-21, -128, and -342 did not go beyond the reference values. The diagnostic significance of miRNA-128, -342 for GCT was 69 %; therefore these miRNAs can be used in a clinical setting. Thus, the increased expression of miRNA-21 and decreased expressions of miRNA-128 and -342 in both blood plasma and saliva indicate cerebral glioma progression. 
    Type of Medium: Online Resource
    ISSN: 2312-3168 , 1814-4861
    URL: Issue
    URL: Article
    DOI: 10.21294/1814-4861-2020-19-3
    DOI: 10.21294/1814-4861-2020-19-3-47-53
    Language: Unknown
    Publisher: Tomsk Cancer Research Institute
    Publication Date: 2020
    detail.hit.zdb_id: 2693095-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
  • 5
    Online Resource
    Online Resource
    The results of use of myoplasty for closure of the pelvic floor defect after extralevator abdominoperineal excision of the rectum
    Tomsk Cancer Research Institute ; 2019
    In:  Siberian journal of oncology Vol. 17, No. 6 ( 2019-01-01), p. 35-40
    Details
    In: Siberian journal of oncology, Tomsk Cancer Research Institute, Vol. 17, No. 6 ( 2019-01-01), p. 35-40
    Abstract: Background. Extralevator abdominoperineal excision is associated with a high incidence of perineal wound complications. There is no uniform standard for choosing the method for pelvic floor reconstruction after extralevator abdominoperineal excision. The purpose of the study was to compare the results of extralevator abdominoperineal excisions of the rectum using various methods of perineal wound closure. Materials and Methods . Between 2014 and 2018, 120 patients underwent extralevator abdominoperineal excisions of the rectum using various options for closure of the pelvic floor. The patients were divided into 3 groups. Group I patients (n=64) underwent simple plasty of the peritoneal wound. Group II patients (n=43) underwent myoplasty using the gluteus maximus muscle. Group III patients (n=13) underwent myoplasty using the rectus abdominis muscle. The incidence of perineal wound complications in the early postoperative period was assessed. Results. The total number of perineal wound complications in Group I, II and III was 33 (51.5 %), 13 (30.2 %), and 6 (46.1 %), respectively. Grade IIIA-IIIB complications according to the Clavien-Dindo classification were observed in 25 % of Group I patients, in 18.6 % of Group II patients and in 7.7 % of Group II patients. Postoperative perineal wound complications occurred more often in Group I patients after simple plasty than in Group II and III patients after myoplasty (51.5 % versus 30.2 %). However, perineal wound complications were observed more often in Group III than in Group II (46.1 % versus 30.2 %, respectively). No significant differences in the frequency of complications between 3 groups were found. Conclusion. Using various options for closure of the pelvic floor after extralevator abdominoperineal excisions of the rectum, there was a tendency to reduction in the incidence of grade IIIA-IIIB perineal wound complications.
    Type of Medium: Online Resource
    ISSN: 2312-3168 , 1814-4861
    URL: Issue
    URL: Article
    DOI: 10.21294/1814-4861-2018-17-6
    DOI: 10.21294/1814-4861-2018-17-6-35-40
    Language: Unknown
    Publisher: Tomsk Cancer Research Institute
    Publication Date: 2019
    detail.hit.zdb_id: 2693095-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Open Access Request
    Availability (electronic / print)
Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages